Novartis Lutathera Combo Therapy Shows Significant Progress in GEP-NETs
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced preliminary results from a Phase III study...
Cancer
AstraZeneca’s Imfinzi Meets Primary Endpoint in Hepatocellular Carcinoma Trial
UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) announced the successful completion of the primary endpoint...
J&J’s Balversa Receives Full FDA Approval for Urothelial Carcinoma Treatment
The US Food and Drug Administration (FDA) has converted the 2019 accelerated approval for Johnson...
Sichuan Kelun-Biotech Secures NMPA Nod for Generic Lynparza Equivalent
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), a Chinese pharmaceutical company, has announced that it...
InnoCare Makes Minjuvi Combo Treatment Available to Patients in China’s GBA
InnoCare (HKG: 9969; SHA: 688428), a China-based biopharmaceutical company, has announced that the combination treatment...
BeiGene Submits Additional Application for Tislelizumab in NSCLC in China
BeiGene (NASDAQ: BGNE) has announced the submission of a supplementary Biologic License Application in China...
Sinocelltech Granted NMPA Approval for Phase I Clinical Trial in Hematological Malignancies
Sinocelltech Group Ltd (SHA: 688520), a biopharmaceutical company based in China, has announced that it...
CARsgen Therapeutics’ CT041 Shows Promising Results in Advanced Solid Tumors at ASCO GI 2024
China-based CAR-T cell specialist CARsgen Therapeutics Holdings Ltd (HKG: 2171) has announced the presentation of...
Beijing Aosaikang Initiates Phase III Trial for Advanced Gastric Cancer Treatment
Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755), a Chinese pharmaceutical company, has registered a Phase...
Eisai and Medivir’s Combo Therapy Advances in Liver Cancer with Positive Trial Results
Japanese pharmaceutical company Eisai’s (TYO: 4523) kinase inhibitor Lenvima (Lenvatinib), combined with Swedish partner Medivir’s...
Luye Pharma’s Biosimilar Bevacizumab Gets GMP Certification in Brazil
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has announced that...
Qilu Pharmaceutical’s Iruplinalkib Gains Additional Indication Approval in China for ALK-Positive NSCLC
The National Medical Products Administration (NMPA) website has indicated that Qilu Pharmaceutical’s Category 1 drug,...
Hengrui Pharmaceuticals Receives NMPA Approval for Phase II Cervical Cancer Study
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval from...
Roche’s Tecentriq SC Receives European Nod as First Subcutaneous PD-(L)1 Therapy
Halozyme Therapeutics (NASDAQ: HALO) has announced that the European Commission (EC) has granted marketing authorization...
RemeGen’s MSLN-Targeted ADC RC88 Clears to Begin Phase I/IIa Study in China
RemeGen Co., Ltd (HKG: 9995; SHA: 688331), a leading Chinese biotech firm, has announced that...
Chipscreen NewWay Biosciences Initiates Phase I Trial for PD-1/CD40 Bispecific Antibody Candidate NWY001
China-based Chengdu Chipscreen NewWay Biosciences Co., Ltd has announced that the first patient has been...
3D Medicines Secures Registration for Envafolimab in Macau for Advanced Solid Tumors
3D Medicines (HKG: 1244), a China-based oncology specialist, has announced the registration of its PD-L1...
Neuboron Medtech Secures Clinical Trial Approval for First BNCT Drug in China
Neuboron Medtech Ltd., based in China, has received clinical trial approval for its borofalan (10b)...
SciClone’s Partner Menarini Files for Elacestrant Approval in Macau for Advanced Breast Cancer
SciClone Pharmaceuticals Inc. (HKG: 6600) has announced that its Italian partner, Menarini Group, has submitted...
RemeGen Secures Fast-Track Designation for RC88 in Platinum-Resistant Ovarian Cancer
China-based biotech RemeGen Co., Ltd (HKG: 9995; SHA: 688331) has received fast-track designation (FTD) from...